2
|
Taguchi K, Ogaki S, Nagasaki T, Yanagisawa H, Nishida K, Maeda H, Enoki Y, Matsumoto K, Sekijima H, Ooi K, Ishima Y, Watanabe H, Fukagawa M, Otagiri M, Maruyama T. Carbon Monoxide Rescues the Developmental Lethality of Experimental Rat Models of Rhabdomyolysis-Induced Acute Kidney Injury. J Pharmacol Exp Ther 2020; 372:355-365. [PMID: 31924689 DOI: 10.1124/jpet.119.262485] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Accepted: 12/26/2019] [Indexed: 02/05/2023] Open
Abstract
Many victims, after being extricated from a collapsed building as the result of a disaster, suffer from disaster nephrology, a term that is referred to as the crush syndrome (CS). Recommended treatments, which include dialysis or the continuous administration of massive amounts of fluid are not usually easy in cases of such mass natural disasters. In the present study, we examined the therapeutic performance of a biomimetic carbon monoxide (CO) delivery system, CO-enriched red blood cells (CO-RBCs), on experimental animal models of an acute kidney injury (AKI) induced by traumatic and nontraumatic rhabdomyolysis, including CS and rhabdomyolysis with massive hemorrhage shock. A single CO-RBC treatment was found to effectively suppress the pathogenesis of AKI with the mortality in these model rats being improved. In addition, in further studies using glycerol-induced rhabdomyolysis model rats, the pathogenesis of which is similar to that for the CS, AKI and mortality were also reduced as the result of a CO-RBC treatment. Furthermore, CO-RBCs were found to have renoprotective effects via the suppression of subsequent heme protein-associated renal oxidative injury; the oxidation of myoglobin in the kidneys, the generation of reactive oxygen species by free heme produced from degraded-cytochrome P450 and hemoglobin-associated renal injury. Because CO-RBCs can be prepared and used at both hospitals and at a disaster site, these findings suggest that CO-RBCs have the potential for use as a novel cell therapy against both nontraumatic and traumatic rhabdomyolysis including CS-induced AKI. SIGNIFICANCE STATEMENT: After mass natural and man-made disasters, people who are trapped in collapsed buildings are in danger of acute kidney injury (AKI), including crush syndrome (CS)-related AKI. This paper reports that carbon monoxide-enriched red blood cells (CO-RBCs), which can be prepared at both hospitals and disaster sites, dramatically suppressed the pathogenesis of CS-related AKI, thus improving mortality via suppressing heme protein-associated renal injuries. CO-RBCs have the potential for serving as a practical therapeutic agent against disaster nephrology associated with the CS.
Collapse
Affiliation(s)
- Kazuaki Taguchi
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Shigeru Ogaki
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Taisei Nagasaki
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Hiroki Yanagisawa
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Kento Nishida
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Hitoshi Maeda
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Yuki Enoki
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Kazuaki Matsumoto
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Hidehisa Sekijima
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Kazuya Ooi
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Yu Ishima
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Hiroshi Watanabe
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Masafumi Fukagawa
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Masaki Otagiri
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| | - Toru Maruyama
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Japan (K.T., Y.E., K.M.); Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (S.O., T.N., H.Y., K.N., H.M., H.W., T.M.) and Center for Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences (H.W., T.M.), Kumamoto University, Kumamoto, Japan; Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan (H.S., K.O.); Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan (Y.I.); and Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan (M.F.)
| |
Collapse
|